GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GeneThera Inc (OTCPK:GTHR) » Definitions » Forward PE Ratio

GeneThera (GeneThera) Forward PE Ratio : 0.00 (As of May. 23, 2024)


View and export this data going back to 2000. Start your Free Trial

What is GeneThera Forward PE Ratio?

GeneThera's Forward PE Ratio for today is 0.00.

GeneThera's PE Ratio without NRI for today is 0.00.

GeneThera's PE Ratio for today is 0.00.


GeneThera Forward PE Ratio Historical Data

The historical data trend for GeneThera's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GeneThera Forward PE Ratio Chart

GeneThera Annual Data
Trend
Forward PE Ratio

GeneThera Quarterly Data
Forward PE Ratio

Competitive Comparison of GeneThera's Forward PE Ratio

For the Biotechnology subindustry, GeneThera's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


GeneThera's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, GeneThera's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where GeneThera's Forward PE Ratio falls into.



GeneThera Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


GeneThera  (OTCPK:GTHR) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


GeneThera Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of GeneThera's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


GeneThera (GeneThera) Business Description

Traded in Other Exchanges
N/A
Address
3051 W 105th Avenue, Suite 350251, Westminster, CO, USA, 80035
GeneThera Inc is a biotechnology company using its proprietary molecular sciences and technologies dedicated to eradicating diseases such as COVID-19, Paratuberculosis, Mad Cow Disease, Chronic Wasting Disease, and E.coli and Salmonella infections. It focuses on developing novel molecular diagnostic tests, therapeutics, and vaccines through its proprietary robotic technologies. Its Molecular Robotic/AI Platform and Therapeutic strategy (MORAPAT) is designed to prevent the spread of disease from animals and at the same time, allow better control of zoonotic infectious agents. The company has also developed a molecular system for the detection of Mycobacterium Avian Paratuberculosis in the milk of infected dairy cows.
Executives
Avel Kolesnikov director 11353 COLONY CIRCLE, BROOMFIELD CO 80020
Mcnece Elmer Roy Jr 10 percent owner 632 CANTRILL DRIVE, DAVIS CA 95616
Fidra Holdings Ltd 10 percent owner CABLE BEACH COURT, ONE WEST BAY STREET, NASSAU BAHAMAS C5 00000
Steven Michael Grubner director, officer: Chief Financial Officer 728 S. PRAIRIE AVENUE, BARRINGTON IL 60010
Antonio Milici director, 10 percent owner, officer: Chief Executive Officer 3930 YOUNGFIELD, WHEAT RIDGE CO 80033
Tannya L Irizarry director, 10 percent owner, officer: Chief Administative Officer 11880 ANTLER TR, LITTLETON CO 80127

GeneThera (GeneThera) Headlines

No Headlines